Tit Albreth
Tit Albreth

Head of Centre /Senior Researcher of the National Institute of Public Health of Slovenia).

PhD, Doctorate of Science - University of Amsterdam, 2011

DSc, Doctor of Science – Erasmus University Rotterdam, 2001

MSc, Master of Science - Erasmus University Rotterdam, 1999

Specialist in Social Medicine - Ministry of Health of Slovenia, 1997

Medical Doctor, degree in medicine - Faculty of Medicine, Ljubljana, SI, 1989

2006-2008 - project manager of the FACT project, supporting the 1st Slovenian Presidency to the European Union

2011-now - scientific coordinator of four EU policy projects on the topic of cancer

PubMed publications:

Social network profile:
Twitter: TitAlbreht
LinkedIn: https://www.linkedin.com/in/tit-albreht-1873826/

Cristóbal Belda Iniesta
Cristóbal Belda Iniesta

General Director Institute of Health Carlos III.
Medical specialist in Medical Oncology and Doctor of Medicine (MD)

Until his appointment as Director of the Carlos III Health Institute, he has been Assistant Director-General of the Carlos III Health Institute (2018-2021), with direct responsibility in the operational management of the Strategic Action in Health, the main assistance programme to promote and coordinate Biomedical Research in Spain.

He is a medical specialist in Medical Oncology and Doctor of Medicine, skilled in the design and implementation of highly complex clinical trials and cancer biomarkers. He is co-author of more than 100 international scientific papers, dozens of chapters in scientific books and director of 9 doctoral theses.

Since 1999, it has been devoted to attend patients diagnosed with brain tumors, lung cancer, and their families, as well as to the research of improving their quality of life.

Most recently, he was the Study Chair and corresponding author of the world's first clinical trial of combined vaccines against SARS-CoV-2 (COMBIVACS), published in The Lancet in June 2021.

In 2010, he began his management career as head of the innovation node of the La Paz University Hospital. Since then, he has held different management positions in public and private organizations, combining this activity with teaching, care and research activities.

He directed the Healing National School, the UNED-ISCIII University Mixed Institute and, from 2015 to 2018, executive director of HM Hospitals Foundation and R&D Director for HM hospitals group.

From the teaching experience perspective;

He has been Associate Professor of Health Sciences at the Faculty of Medicine of the Autonomous University of Madrid and the CEU San Pablo University.
Regular collaborator in master's degrees and postgraduate courses at several Spanish universities focused both Oncology and education in Health and Research Management.

From the social perspective;

He is Trustee of the Molina de Segura Medical Studies Foundation (Murcia-Spain), a non-profit entity focused in the promotion of scientific vocations in young people.

He belongs to the UNED Social Council representing social interests. Lastly, he is a member of the Academic Council of the FIDE Foundation, a think-tank oriented to the multidisciplinary debate of legal-economic issues.


Caroline Berchet
Caroline Berchet

Health Economist. OECD

Caroline holds a PhD from the University Paris-Dauphine (FRANCE), which explored inequalities in health and health care use.

Caroline Berchet (PhD) is a health economist at the OECD Health Division, working on a broad variety of topics related to both data and policy analysis. Her work on data focuses on health system performance assessment framework and how to improve the current health information system. On the policy side, Caroline manages the OECD work on cancer care, and has also been working on quality and health care policies, and on health system efficiency across OECD countries.

Josep Mª Borrás
Josep Mª Borrás

Director Cancer Plan, Department of Health 

MD and PhD (Autonomous University of Barcelona) Epidemiologist

Cancer Planning and control at regional and national level
Health Services Research
WP Leader in CraNE Joint Action

Paolo Casali
Paolo Casali

Director of Medical Oncology Unit 2. Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy

Medical degree; Specialty degree in Clinical Oncology; Specialty degree in Haematology

Paolo G. Casali's clinical and research activities focus on sarcomas. He coordinated the Joint Action on Rare Cancers (JARC) of the European Union, carried out between 2016 and 2019, and is currently coordinating the Joint Action on Networks of Expertise (JANE). He served as the Secretary of the Italian Sarcoma Group from 2002 to 2021, currently being a member of its Technical-scientific Committee, and is a member of the Soft Tissue & Bone Sarcoma Group of the European Organisation for Research and Treatment of Cancer (EORTC). He is a member of the Sarcoma Faculty of the European Society for Medical Oncology (ESMO). He chairs the Sarcoma domain of EURACAN, the European Reference Network on rare adult solid cancers. He is a member of the Coordination group of the Italian National Network on Rare Cancers and a member of the Coordinating body of the Regional Oncology Network of Lombardia Region. He is a member of the Public Policy Committee of ESMO, having previously served as a member of its Council and Executive Board. He also served as member of the Board of Directors of the European CanCer Organization (ECCO) and the Board of Directors of the Connective Tissue Oncology Society (CTOS).
He is (co)author of more than 330 papers in peer-reviewed medical journals (h-index: 96).

Social network profile: @casali_pg

Andreas Charalambous
Andreas Charalambous


Social networking profile: @AndreasC466 (Twitter) 

BSc, MSc, PGCert (Research), PhD (Oncology Nursing), started his nursing career in 1995. He obtained his BSc in Nursing Science in 1999 by the Northumbria University (U.K), his MSc (Nursing Science) in 2002 and his PhD (Oncology Nursing) in 2008 from Middlesex University (UK). 

He works as a Professor of Oncology and Palliative Care at the Cyprus University of Technology and he also holds the position of an Adjunct Professor at University of Turku (Finland).
He is the founder and Past-President of the Cyprus Oncology Nursing Society. He has served as President of the European Oncology Nursing Society (EONS) and he is currently President of the European Cancer Organization. He is also the Founder of the Cancer Nursing Fund (https://cancernurse.eu/cancer-nursing-fund/) and Founder of the European Cancer Communities Foundation (https://www.europeancancerfoundation.org/).

He is involved in National and International research programs (HORIZON2020, ERASMUS+, COST) in various fields of cancer care. Examples of externally funded projects include: PI in the ERASMUS+ project PROLEPSIS (https://prolepsis.eu/), SAVE (https://www.projectsave.eu/save/) and PI (Cyprus team) in the ERAMUS+ project HERO (https://hero-erasmus.csl.gr/) and eLILY (https://elily.eu/about-the-project/), PI (Cyprus team) in the HORIZON project INCISIVE (https://incisive-project.eu/) and EU4HEALTH project TRANSiTION.
He has published over 200 National and International publications in esteem journals. H-index 35 and i10-index 76

Ana Clopés Estela
Ana Clopés Estela

Pharmacy Director. Catalan Institute of Oncology (ICO)

Bachelor of Pharmacy, University of Barcelona 1991. PhD. Autonomous University of Barcelona, 2016. Specialist Pharmacist in Hospital Pharmacy, 1994. 

Pharmacy Director at the Catalan Institute of Oncology (ICO) since 2007.
Deputy Director at the Catalan Institute of Oncology (ICO) from October 1, 2018, to June 2022.
Director of Care Support at the Catalan Institute of Health (ICS) from April 2016 to July 2018.
Head of the Pharmacy Department at the Catalan Institute of Oncology since 2003.

Associate Professor, Faculty of Pharmacy, Ramon Llull University
Barcelona since 2019. Member of the Medicinal Products
Policy Advisory Committee of the Ministry of Health since 2019.


Enriqueta Felip
Enriqueta Felip

Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain

President Spanish Society of Medical Oncology (SEOM) 2021-2023

Enriqueta Felip received her degree in Medicine and Surgery from the Autonomous University of Barcelona (UAB), where she also completed her studies for a PhD in Medical Oncology. She has been an Associate Professor at the UAB from 2010 to May 2019. She is nowadays, Professor of Medicine at the Universitat de Vic (UVicc-UCC). She has an extensive professional career and accredited experience in the oncology sector, as well as knowledge in the scientific and research field. She is currently Section Chief of the Medical Oncology Service at Vall d'Hebron University Hospital and the Principal Investigator of the Vall d'Hebron Institute of Oncology's Thoracic Tumors Cancer Group. 

Enriqueta Felip has made a significant contribution to cancer research, especially in the field of thoracic tumors, and has collaborated in the development of lung cancer approaches that define the current standard of care for the disease. Dr Felip has been involved in several initiatives with scientific organizations, among them, as member of the Board of Directors of the International Association for the Study of Lung Cancer (IASLC, 2017-2021). She is currently a member of the Scientific Committee of the Institut d'Investigació i Innovació Parc Taulí. Throughout her career, she has obtained several recognitions for her work in the oncology field. In 2015, she was awarded with the first Women for Oncology Award from the European Society of Medical Oncology (ESMO). Recently she has been awarded with the Prize “La Vanguardia de la Ciencia” (May 2022). Dr Felip featured on Clarivate Analytics' annual Global Highly Cited Researchers List 2018, 2019, 2020, 2021 and 2022. Enriqueta Felip has authored more than 350 peer-reviewed manuscripts.

Dr Felip is currently the President of the Spanish Society of Medical Oncology (SEOM) 2021-2023 and the President of the Oncologic Comission at Vall d’Hebron University Hospital, Barcelona, Spain.

Social network profile:
@EnriquetaFelip; @_SEOM 


Marta Gómez Quintanilla
Marta Gómez Quintanilla

CDTI. Horizon Europe Health Cluster Spanish Representative

Social network profile: https://www.linkedin.com/in/martagq/

Bachelor's degree in biology with a master's degree in biotechnology.

Work experience: She has been working since 2003 for the Centre for the Technological Development and Innovation Technology (CDTI), a public entity within the Ministry of Science and Innovation; the Business Innovation Financing Agency. In this capacity, Marta’s work is fully dedicated to European Framework Programmes for Research & Innovation, from FP6 to the current Horizon Europe.

Other merits: She is currently appointed as Spanish Representative of the Health Cluster in Horizon Europe and Delegate in the Innovative Health Initiative (IHI) and the subgroup of the Cancer Mission.

Ellen Griesshammer
Ellen Griesshammer

European Cancer Centre Certification Programme. German Cancer Society

Master in Public Health
Master in Social and Developmental Science

Since 2017 in charge of the European Cancer Centre Certification Programme hosted by the German Cancer Society e.V, Berlin Germany
Since 2022 Managing Director of the Institute of Quality in Oncology

Deputy WP leader Joint Action iPAAC, CraNE and CSA CCI4EU


César Hernández García
César Hernández García

Director General de Cartera Común y Farmacia. Ministerio de Sanidad (España)

Doctor en Medicina y Cirugía. Especialista en reumatología

Médico reumatólogo, Hospital Clínico San Carlos (HCSC), Madrid (1994-2002 y 2005-2009)
Subdirector médico del HCSC (2002-2005)
Jefe de Departamento de Medicamentos de Uso Humano, Agencia Española de Medicamentos y Producto Sanitarios (2009-2022)
Director General de Cartera Común y Farmacia (desde 2022)

Victoria Mateos Manteca
Victoria Mateos Manteca

Head of Unit and Professor of Haematology. University Hospital of Salamanca, Spain

Dr. María-Victoria Mateos, MD, PhD, is Head of Myeloma and clinical trials Unit at the Haematology Department and Professor of Medicine at the University of Salamanca, Spain.

She has served on the American Society Hematology Scientific Committee on plasma cell diseases between 2015-2019 and on the EHA’s Scientific Program Committee and Advisory Board since 2013 until 2020 being chair of the Scientific Program Committee in 2019.
She has been Councillor on the EHA Board since 2015 for a four-year mandate and currently she is member of the European School of Haematology (ESH) Scientific committee, member of the ASCO scientific program committee and member of the Executive Committee of the International Myeloma Society.. She received the Briand Durie Award in 2019, the Bart Barlogie Award in 2022 recognizing excellence in myeloma research and the Kyle life time achievement award in 2023. She is the President of the National Society of Hematology since October 2022 for a four-year mandate.

She serves as co-coordinator of GEM (Spanish Myeloma Group), with direct involvement in the design and development of clinical trials. She has coordinated many clinical trials especially in the setting of transplant ineligible and smoldering myeloma and these trials have profoundly influenced current options for the management of these patient populations. She is involved in the clinical research with the novel immunotherapies strategies including CAR-T cells.
She has published over 400 papers in international journals with a H index of 96.

Social network profile: @mvmateos

Ana Molina Barceló
Ana Molina Barceló

Foundation for the Promotion of Health and Biomedical Research in the Valencian Community (FISABIO)

Head of Cancer and Public Health Research Unit

PhD in Public Health (University of Valencia), Degree in Sociology and Master’s degree in Sociology and Anthropology of Public Policy. I am specialised in quality and equity in cancer prevention and control since 2008. My training and expertise in both social and health sciences has favoured a multidisciplinary approach from a theoretical as well as a methodological point of view.

She is the head of the Cancer and Public Health Research Unit at the Biomedical Research Foundation FISABIO since 2017. She has participated in and led national and international research projects on social and gender inequalities in cancer prevention and control and on evaluating the benefits and harms of cancer screening programmes. She has  participated as a speaker and moderator in numerous international and national conferences. Moreover, she regularly participates in activities with the objective of bringing science closer to society. My research results have supported organizational and managerial improvements in regional cancer screening programmes with the aim of reducing inequalities in cancer and improving quality. She has conducted training and teaching activities for health professionals, research staff and students, including lectures at the University of Valencia for both undergraduate and postgraduate degrees. 

Her research results have been published as scientific articles in high-impact indexed journals (52 scientific articles, 23 of them as a senior researcher, and 22 of them being published in first-quartile journals). I have also published books (1 book and 7 book chapters), technical health reports (31 scientific reports) and wide-public aimed science journals (3 popular science article), in addition to other publications (a total of 21). I supervise university degree final projects regularly and mentor medical doctors at the internship stage. I am currently co-directing 3 doctoral theses. She has obtained 1 competitive grant for predoctoral students.

She is a member of the Spanish Society of Epidemiology Screening Group, as well as the Spanish Screening Network and the International Cancer Screening Network. I´m also part of the COVID19 and Cancer Global Modelling Consortium and the Cancer Inequality Registry Working Group from the European Commission DG SANTE. She has been acknowledged by Valencia Regional Ministry of Health for including gender in health research.

Annika Nowak
Annika Nowak

Head of Sector Cancer Mission Secretariat. European Commission - DG RTD unit D.1 Combatting Diseases

Law studies at Humboldt-Universität zu Berlin

Currently : Head of Sector, DG RTD - Cancer mission secretariat
May 2019 - June 2021 : Policy Officer, DG RTD - Health Research
Nov. 2014 - April 2019 : Member of Cabinet, Commissioner for Health and Food Safety
April 2009 - Nov. 2014 : Policy Officer/Team leader, DG SANTE - Health Syste

Social network profile: https://www.linkedin.com/in/annika-nowak-24b55492/

Simon Oberst
Simon Oberst

(Organisation of European Cancer Institutes (OECI))

Direct or of Quality and Accreditation. Organisation of European Cancer Institutes

MA Hons History (Cambridge, UK)
Fellow of the Institute of Chartered Accountants of England and Wales

Simon Oberst is Director of Quality and Accreditation, Organisation of European Cancer Institutes (OECI). He was until recently Director of Clinical Development, Cancer Research UK Cambridge Centre; and concurrently Chair of the Accreditation and Designation Board of the OECI.

Simon is a specialist in quality systems and organisational development in cancer. After graduating from Trinity College, Cambridge, he was a consultant with KPMG and PricewaterhouseCoopers. After spells in industry and charities, he moved to being Director of Improving Cancer Services with the UK’s leading cancer patient charity, Macmillan Cancer Support.

As Director of Clinical Development for the Cancer Research UK Cambridge Centre for 10 years, Simon Oberst was working with University of Cambridge and Cambridge University Hospital leaders to deliver a state of the art 25,000 M2 Cancer Research Hospital on the Cambridge Biomedical Campus.

As chair of the Accreditation Board of OECI since 2015 he has overseen the accreditation of over 50 of the leading Cancer Centres in Europe, as well as establishing consensus quality standards for cancer centres and networks. He has been a key author on subjects such as: bridging research and clinical care – the comprehensive cancer centre. As Director of Quality and Accreditation for OECI, he fosters OECI’s involvement with some of the EU Actions in cancer arising from Europe’s Beating Cancer Plan and Horizon Europe, including CraNE,4UNCAN.eu and Interact. From 1 May he has been co-PI for OECI of the EU Action – Comprehensive Cancer Infrastructures for the EU, CCI4EU.

Key Publications:

Oberst S. Bridging research and clinical care – the Comprehensive Cancer Centre. Mol Oncol. 2019;13:614—18.

Oberst S, van Harten W, Sæter G, et al. 100 European core quality standards for cancer care and research centres. Lancet Oncol. 2020;21:1009—11.

Kehrloesser S, Oberst S, Westerhuis W, et al. Analysing the attributes of Comprehensive Cancer Centres and Cancer Centres across Europe to identify key hallmarks. Mol Oncol. 2021;15(5):1277—1288.

Rosario Perona
Rosario Perona

Instituto de Salud Carlos III.
Research Professor. Coordinator of  Cancer Mission Mirror  group for ISCIII  in SPAIN.

-PhD in Pharmacy, Universidad Complutense de Madrid, 1979- 1982. Since then as assistant, associate Professor and finally since 2010  Research Professor at Consejo Superior de Investigaciones Cientificas. Actually  Research Professor at Instituto de Salud Carlos III, associated to the Director Team.

She has been working in cancer reseach: drug resistance and new tharapies since 1993.  H index 36. Pi of 30 competitive research  projects in cancer and 125 accepted manuscripts in indexed journals. President of ASEICA and FESEO Cancer societies (2004-2006). Member of  EACR executive committee (2006-2010). Deputy Director of Evaluation and Promotion of Research from Instituto de Salud Carlos III. 

She is currently Coordinator of Mision Cancer Mirror group for ISCIII  in SPAIN and member of the Strategic group of Cancer Mission in Spain.

Ramón Reyes
Ramón Reyes

Presidente Asociación Española Contra el Cáncer

Social network profile:
Linkedin: https://www.linkedin.com/in/ramon-reyes-2b10042/
Twitter: https://twitter.com/RamonReyesCC 

Doctor en Ciencias y Licenciado en Bioquímica por la Universidad Complutense de Madrid

Ejerció como Profesor adjunto en la Universidad Autónoma de Madrid y ha trabajado en investigación en el Centro de Biología Molecular (CBM) de Madrid. Ha desempeñado diversas responsabilidades de dirección en la Industria Farmacéutica y ha sido Socio responsable para España de las prácticas de Salud y Tecnología en la firma global de Consultoría de Dirección, Egon Zehnder. Actualmente ocupa como voluntario los cargos de Presidente de la Asociación Española Contra el Cáncer, Presidente de la Fundación Científica de la Asociación Española Contra el Cáncer, Comisionado de Salud y Cuidados en la Plataforma del Tercer Sector

Juan Antonio Roca
Juan Antonio Roca

Associate Professor in Department of Commercial Law and Roman Law. University of Granada
Social network profile: https://www.linkedin.com/in/juan-roca-fern%C3%A1ndez-castanys-4720b048/?originalSubdomain=es CURRICULUM

Education (name of degree or studies):
Bachelor's Degree in Law (University of Granada)
Doctoral thesis in commercial law cum laude (University of Bologna)
Work experience (specifically related to the theme of the activity) Associate Professor at the University of Granada since 1994, where he splits his time doing research and teaching two subjects, Commercial Law 1 and Commercial Law 2.
Professor in the following masters:
• Master's Degree in Legal Practice
• Master's Degree in Business Administration and Law Consultancy
• Master's Degree in Business Law

Other merits related to the activity:
• Award from the Academy of Jurisprudence and Legislation of Granada on Commercial Law , 1991.
• X Award of General Mutuality on Law professionals.
• Award “Avvocato Domenico Belvedere” on The Best Doctoral Thesis, Bologna 1991.
• Member of de Royal Academy of Jurisprudence and Legislation.

Matthias Schuppe
Matthias Schuppe

Deputy Head of Unit. European Commission - DG SANTE

Mag. Phil. Political Science, Economics, International Law (University of Salzburg), MSc. International Political Economy (London School of Economics), MSc. Health Services and Systems Research (London School of Hygiene and Tropical Medicine)

Since October 2019 leader of the DG SANTE Cancer Task Force. From October 2022 Deputy Head of Unit of the Cancer and Health in all policies unit in DG SANTE. Prior work experience in the Commission include country knowledge / health information and communicable diseases (HIV, TB, hepatitis).  

Josep Tabernero Caturla
Josep Tabernero Caturla

Degree in Medicine and Surgery with special prize (“Extraordinary degree prize”) and PhD, Universitat Autònoma de Barcelona, Barcelona, Spain

Healthcare Management Program. IESE Business School. Madrid, Spain (2013)

Executive Master in Healthcare Organizations Leadership. ESADE Business School. Barcelona, Spain (2014)

Research Accreditation: Associate Professor. Catalan University Quality Assurance Agency, AQU Catalunya. Barcelona, Spain (2016)

Research Accreditation: Full Professor. Catalan University Quality Assurance Agency, AQU Catalunya. Barcelona, Spain (2018)

Currently Head of the Medical Oncology Department at the Vall d’Hebron University Hospital, Director of the Vall d’Hebron Institute of Oncology (VHIO) and Professor of Medicine at the Universitat de Vic/Universitat Central de Catalunya

He serves on the Editorial Boards of various top tier journals including Annals of Oncology, ESMO Open, Cancer Discovery, Clinical Cancer Research, Cancer Treatment Reviews, and Nature Reviews Clinical Oncology. He has (co) authored approximately 600 peer-reviewed papers with an H-Index of 112.
He was the President (2018 – 2019) and member of the Executive Board (2016-2021) of the European Society for Medical Oncology´s (ESMO). Also he was member of the General Assembly for Cancer Mission (2018-2020).

Social network profile:
Twiter: @TaberneroJosep   
LinkedIn: https://www.linkedin.com/in/josep-tabernero/